The investigation centers on a stark reversal in financial performance. During a February 2026 earnings call, CFO David Barter expressed confidence in the company's momentum, projecting annual recurring revenue (ARR) between $567 million and $573 million. However, by the second quarter, those expectations were downgraded to a range of $550 million to $560 million, with actual ARR performance appearing flat compared to the previous year.
Cellebrite DI Faces Shareholder Probe Following Stock Sell-Off
A sharp 30% decline in Cellebrite DI Ltd. shares following the company's second-quarter 2026 earnings report has triggered a formal investigation by the law firm Levi & Korsinsky. The inquiry focuses on whether management misled investors regarding revenue projections and the company's growth trajectory earlier this year.
Levi & Korsinsky, a firm recognized by the ISS Securities Class Action Services, is now reviewing whether these earlier disclosures constituted materially false or misleading statements. Investors who purchased CLBT securities and suffered financial losses are being asked to submit brokerage records for a potential recovery evaluation. The firm maintains that eligibility for the investigation depends on purchase dates rather than current share ownership, and they are handling the matter on a contingency basis.
Comments (0)
No comments yet. Be the first!